These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 10791510)
1. Pharmacoeconomic analyses: making them transparent, making them credible. Rennie D; Luft HS JAMA; 2000 Apr; 283(16):2158-60. PubMed ID: 10791510 [No Abstract] [Full Text] [Related]
2. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. Hill SR; Mitchell AS; Henry DA JAMA; 2000 Apr; 283(16):2116-21. PubMed ID: 10791503 [TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomics. Ahuja J; Gupta M; Gupta AK; Kohli K Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600 [TBL] [Abstract][Full Text] [Related]
7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example. Weintraub WS J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905 [TBL] [Abstract][Full Text] [Related]
10. How much faith can we have in pharmacoeconomic analyses? Hatoum HT; Kong SX Pharmacoeconomics; 1994 Dec; 6(6):584-6. PubMed ID: 10155288 [No Abstract] [Full Text] [Related]
11. A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics. Garattini L; Grilli R; Scopelliti D; Mantovani L Pharmacoeconomics; 1995 Jan; 7(1):1-6. PubMed ID: 10155289 [No Abstract] [Full Text] [Related]
12. The FDA and regulation of cost-effectiveness claims. Neumann PJ; Zinner DE; Paltiel AD Health Aff (Millwood); 1996; 15(3):54-71. PubMed ID: 8854508 [TBL] [Abstract][Full Text] [Related]
13. A model to transfer trial-based pharmacoeconomic analyses to clinical practice. Gandjour A Pharmacoeconomics; 2011 Feb; 29(2):97-105. PubMed ID: 21244101 [TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement]. Hoomans T; van der Roer N; Severens JL; Delwel GO Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045 [TBL] [Abstract][Full Text] [Related]
15. Evaluation and review of pharmacoeconomic models. Hay JW Expert Opin Pharmacother; 2004 Sep; 5(9):1867-80. PubMed ID: 15330725 [TBL] [Abstract][Full Text] [Related]
16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
18. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace. Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999 [TBL] [Abstract][Full Text] [Related]
19. The rationale of pharmacoeconomic analysis in rheumatologic indications. Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796 [TBL] [Abstract][Full Text] [Related]